Exolaunch Successfully Deploys Satellites on Historic Ariane 6 Inaugural Launch, Enhancing European Access to Space
Exolaunch, the global leader in launch mission management, integration, and satellite deployment services, proudly announced the successful deployment of four satellites aboard Arianespace’s Ariane 6 maiden flight. The liftoff occurred on Tuesday, July 9 at 1600 GFT from the Guiana Space Centre, also known as Europe's Spaceport, in Kourou, French Guiana. Representing customers ESA, NASA, and Spacemanic, this mission highlights Exolaunch’s crucial role in broadening access to space and supporting new launch vehicle providers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709995719/en/
The historic Ariane 6 liftoff occurred on Tuesday, July 9 at 1600 GFT from the Guiana Space Centre, also known as Europe's Spaceport, in Kourou, French Guiana. Photo credits: ESA, Arianespace, CNES.
This historic launch featured ESA’s ISTSat-1 and 3Cat-4, NASA’s CURIE, and Spacemanic’s GRBBeta satellites. The successful deployment of these satellites underscores Exolaunch’s commitment to facilitating groundbreaking scientific research and technological advancements through reliable and innovative satellite deployment solutions.
ESA’s ISTSat-1, developed by students at the Instituto Superior Técnico in Lisbon, aims to demonstrate ADS-B technology, validating detection capabilities and assessing antenna and receiver performance for receiving messages from commercial aircraft. 3Cat-4, a CubeSat from Universitat Politécnica de Catalunya, features a flexible microwave payload technology demonstrator with scientific objectives related to GNSS for Earth observation and AIS receiver validation.
NASA’s CURIE mission comprises two near-identical 3U CubeSats designed to explore low-frequency radio interferometry in space. These CubeSats will study solar radio bursts by maintaining a 1-3 km separation post-deployment, contributing to the understanding of heliospheric space weather and serving as a proof of concept for future space-based interferometry observatories.
Spacemanic’s GRBBeta, a 2U CubeSat, acts as a tech demonstration for the future CAMELOT constellation, aiming to detect and localize gamma-ray bursts from space. Managed by Spacemanic and led by the Technical University of Košice, this mission tests new subsystems, including an advanced GNSS positioning module and a radio modem for instant telemetry.
The successful launch of Ariane 6 represents a significant milestone for the European space industry, heralding a new era of enhanced access to space for European entities. Ariane 6 is designed to offer flexibility and cost-efficiency, making it an attractive option for various space missions. Through supporting this historic launch, Exolaunch reinforces its dedication to fostering growth and innovation in Europe’s space sector.
"Exolaunch is honored to have been part of the Ariane 6 maiden flight, working alongside Arianespace, ESA, and CNES to provide our customers with dependable access to space,” remarked Jeanne Allarie, chief commercial officer at Exolaunch. “We also extend congratulations to ESA, NASA, and Spacemanic on their successful satellite deployments. We are proud to support these innovative missions and look forward to the scientific and technological advancements they will each bring. This launch is not only a testament to the technical prowess and collaborative spirit of the European space community, but also a stepping stone towards a more robust, competitive European presence in the global space industry. We look forward to the opportunity to support future Ariane 6 launches and ensure that Europe remains at the forefront of space exploration.”
About Exolaunch
Exolaunch (Germany, USA) is a global leader in launch mission integration and deployment technologies. With a decade of flight heritage and nearly 400 satellites launched across 29 missions to date, Exolaunch leverages industry insight to tailor turnkey solutions that meet customer needs and respond to market trends. Exolaunch fulfills launch contracts for industry leaders, the world's most innovative start-ups, research institutions, government organizations, and international space agencies. The company develops and manufactures its own flight-proven and industry-leading small satellite separation systems, with the fastest-growing heritage on the market. Exolaunch promotes safe, sustainable, and responsible use of space and is committed to making space accessible for all.
For more information, please visit www.exolaunch.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709995719/en/
Contacts
For media inquiries, please contact media@exolaunch.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom